NCT02032277 arm group eadcf9719ca318741e845be57e630f6a [clinicaltrials_resource:NCT02032277/arm-group/eadcf9719ca318741e845be57e630f6a]
Paclitaxel [clinicaltrials_resource:2faf0231045589a666cbf07e1855164d]Doxorubicin [clinicaltrials_resource:675e17967a0b31eb9364aaa390d78cca]Carboplatin [clinicaltrials_resource:89da5ff05cc21db6a5e861d95217cc07]Veliparib [clinicaltrials_resource:c1e963efaa809ebad27fa5608d271651]Cyclophosphamide [clinicaltrials_resource:f6a469432f61a625d08d86724ed958a1]clinicaltrials:NCT02032277
arm group [clinicaltrials_vocabulary:arm-group]
NCT02032277 arm group eadcf9719ca318741e845be57e630f6a [clinicaltrials_resource:NCT02032277/arm-group/eadcf9719ca318741e845be57e630f6a]
Bio2RDF identifier
NCT02032277/arm-group/eadcf9719ca318741e845be57e630f6a
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... dcf9719ca318741e845be57e630f6a
description [clinicaltrials_vocabulary:description]
Veliparib + carboplatin + paclitaxel followed by doxorubicin/cyclophosphamide (AC)
identifier
clinicaltrials_resource:NCT02032277/arm-group/eadcf9719ca318741e845be57e630f6a
title
NCT02032277 arm group eadcf9719ca318741e845be57e630f6a
@en
type
label
NCT02032277 arm group eadcf971 ...... cf9719ca318741e845be57e630f6a]
@en